Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial (Q46527122)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 July 2015

Language	Label	Description	Also known as
English	Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial	scientific article published on 28 July 2015

Statements

scholarly article

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial (English)

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Maximilian von Eynatten

11

object named as

Maximilian von Eynatten

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

Berthold Hocher

object named as

Berthold Hocher

7

0 references

Per-Henrik Groop

1

1 reference

Europe PubMed Central

22 December 2017

author name string

Mark E Cooper

2

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

Vlado Perkovic

3

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

Kumar Sharma

4

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

Guntram Schernthaner

5

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

Masakazu Haneda

6

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

Maud Gordat

8

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

Jessica Cescutti

9

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

Hans-Juergen Woerle

10

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

language of work or name

0 references

publication date

28 July 2015

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

Diabetes and Vascular Disease Research

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

12

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

6

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

455-462

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Standards of medical care in diabetes--2014

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells.

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis.

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Sitagliptin reduces albuminuria in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1177%2F1479164115579002

21 January 2018

Identifiers

10.1177/1479164115579002

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

1 reference

Europe PubMed Central

22 December 2017

http://europepmc.org/abstract/MED/26224765

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46527122&oldid=2116226727"